Sonnet BioTherapeutics

OverviewSuggest Edit

Sonnet BioTherapeutics is an oncology-focused biotechnology company. Its proprietary FHAB (Fully Human Albumin Binding) technology enables the development of targeted biologic drugs with enhanced single- or bi-specific mechanisms. The FHAB platform utilizes a human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.
HQPrinceton, NJ, US

Latest Updates

Employees (est.) (Apr 2020)30
Revenue (FY, 2019)$30.1 M(-25%)
Share Price (Jun 2021)$1.5(+2%)
Cybersecurity ratingAMore

Key People/Management at Sonnet BioTherapeutics

Pankaj Mohan

Pankaj Mohan

Founder, CEO & Chairman
Jay Cross

Jay Cross

Chief Financial Officer
John K. Cini

John K. Cini

Chief Scientific Officer & Co-Founder
Susan Dexter

Susan Dexter

Chief Technical Officer
Show more

Sonnet BioTherapeutics Office Locations

Sonnet BioTherapeutics has an office in Princeton
Princeton, NJ, US (HQ)
100 Overlook Center
Show all (1)

Sonnet BioTherapeutics Financials and Metrics

Sonnet BioTherapeutics Revenue

Sonnet BioTherapeutics's revenue was reported to be $30.14 m in FY, 2019

Net income (Q2, 2021)


EBIT (Q2, 2021)


Market capitalization (4-Jun-2021)


Closing stock price (4-Jun-2021)


Cash (31-Mar-2021)



Sonnet BioTherapeutics's current market capitalization is $26.2 m.
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020



General and administrative expense


R&D expense


Operating expense total

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q3, 2020Q1, 2021Q2, 2021



General and administrative expense


R&D expense


Operating expense total

USDQ2, 2011

Financial Leverage

1.7 x
Show all financial metrics

Sonnet BioTherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Sonnet BioTherapeutics Online and Social Media Presence

Embed Graph

Sonnet BioTherapeutics News and Updates

Thinking about buying stock in Sonnet BioTherapeutics, CHF Solutions, Harmonic Inc, Tiziana Life Sciences, or Seanergy Maritime Holdings?

NEW YORK, Aug. 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SONN, CHFS, HLIT, TLSA, and SHIP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Sonnet BioTherapeutics Blogs

Sonnet BioTherapeutics Announces Issuance of U.S. Patent for Platform Technology

U.S. Patent and Trademark Office issued US Patent No. 11,028,166 for the Company's Fully Human Albumin Binding Domain Fusion Proteins PRINCETON, NJ / ACCESSWIRE / June 8, 2021 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a biopharmaceutical company developing innovative targeted biologic d…

Sonnet BioTherapeutics Provides Fiscal Year 2021 Second Quarter Business and Earnings Update

SON-1010, fully-human IL-12 configured using FHAB platform, advancing towards IND submission At-The-Market offering program resulted in net proceeds of $10.2 million PRINCETON, NJ / ACCESSWIRE / May 17, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a bioph…

Sonnet BioTherapeutics Completes Successful GLP Repeat Dose Toxicology Study of IL12-FHAB (SON-1010) in Non-Human Primates (NHP)

The No Observed Adverse Event Level (NOAEL) following repeated administration was more than 50 times the anticipated equivalent human clinical dose in NHP with no evidence of cytokine release syndrome. Pharmacokinetic (PK) analysis of serum samples confirmed an enhanced profile of IL12-FHAB over re…

Sonnet BioTherapeutics Completes Licensing Agreement with New Life Therapeutics

New Life Therapeutics (NLT) to develop low-dose Interleukin 6 for Diabetic Peripheral Neuropathy in ASEAN territories Upfront and potential milestone payments totaling up to $21 Million with up to 30% royalties on commercial sales NLT to fund Phase 1b/2a clinical trial and submit an IND planned for…

Sonnet BioTherapeutics Provides 2021 Business Update

PRINCETON, NJ / ACCESSWIRE / March 29, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today a business update on its ongoing programs. "Last year we continued execution acros…

Sonnet BioTherapeutics Appoints Richard Kenney as Chief Medical Officer and Manuel Dafonseca as Head of Clinical Operations

PRINCETON, NJ / ACCESSWIRE / March 22, 2021 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today the appointment of Richard Kenney, M.D. as Chief Medical Officer and Manuel Dafons…
Show more

Sonnet BioTherapeutics Frequently Asked Questions

  • When was Sonnet BioTherapeutics founded?

    Sonnet BioTherapeutics was founded in 2011.

  • Who are Sonnet BioTherapeutics key executives?

    Sonnet BioTherapeutics's key executives are Pankaj Mohan, Jay Cross and John K. Cini.

  • How many employees does Sonnet BioTherapeutics have?

    Sonnet BioTherapeutics has 30 employees.

  • Who are Sonnet BioTherapeutics competitors?

    Competitors of Sonnet BioTherapeutics include Accelerated Pharma, Arcellx and IDP Pharma.

  • Where is Sonnet BioTherapeutics headquarters?

    Sonnet BioTherapeutics headquarters is located at 100 Overlook Center, Princeton.

  • Where are Sonnet BioTherapeutics offices?

    Sonnet BioTherapeutics has an office in Princeton.

  • How many offices does Sonnet BioTherapeutics have?

    Sonnet BioTherapeutics has 1 office.